O n a global basis, cervical cancer still generates close to half a million new cases per year, of which half would die as a consequence. These figures are strongly related to socioeconomic level of development, with the burden of the disease heavily affecting developing populations.
We now understand the causes of cervical cancer and novel prevention methods are being developed and introduced into medical practice. It is thus the hopeful beginning of a time that should result in the drastic reduction of cervical cancer worldwide.
Mexico cumulates risk factors for cervical cancer. The prevalence of Human Papillomavirus (HPV) DNA in women above 35 years of age is as high as 15%, parity is high in most social groups and screening offers a limited coverage for a substantial proportion of the population.
In spite of efforts, the organization of screening programs such as the ones conceived and implemented in North America and in some countries in Europe has been of limited value.
For most populations it is not possible to demonstrate neither that cytology-based programs are improving nor that cervical cancer mortality is being reduced as a consequence.
This scenario is and has been dismayingly similar to other countries in the region and current estimates of the number of invasive cervical cancer still indicate some 70 000 new cases per year occur in Central and South America, with a high mortality rate.
When in the early 80's the technology was developed to allow testing for the DNA of the HPV in exfoliated cervical cells, the field exploded. With these resources, epidemiological studies were able to confirm that most of the observed risk associations were in fact mediated by the persistent presence of HPV DNA. The finding is of utmost importance because the high-risk types of HPV seem to be necessary for the development of all cervical cancer cases worldwide. As a consequence,
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Cervical cancer: Advances in prevention and knowledge of its etiology the strategy for prevention has rapidly evolved towards the incorporation of HPV tests as a screening tool and the testing of novel HPV vaccines. Fortunately, the number of HPV types involved in invasive cervical cancer is limited. With little geographical variation, a vaccine that would include the seven most common HPV types in cervical cancer (HPV 16, 18, 45, 31, 33, 52 and 58) would effectively prevent 87% of cases among vaccinated women. Moreover, the risk of cervical cancer for any given high-risk type of the 15 most commonly found, is not statistically different from the risk reported for the most common ones, HPV 16 and HPV 18. Therefore, under current evidence, group testing of clinical specimens for a cocktail of highrisk types should be sufficient for screening and patient management. HPV vaccines are still under evaluation, but HPV testing equipment is commercially available and FDA licensed.
A sufficient number of well-conducted studies has already been published using such cocktails and also some of the best Polymerase Chain Reaction (PCR) systems available. They have all consistently shown that any of the two, Hybrid Capture 2 (HC 2) or the GP5+/6+ PCR/EIA have sensitivities for cervical intraepithelial neoplasia 3 (CIN 3) and cervical cancer at least equal and in most studies significantly better than cervical cytology. Under no controlled conditions, cytology has resulted to be superior to HPV tests. In contrast, the specificity of HPV tests is age dependent. In the young age groups the specificity of the HPV tests is lower than cytology and, in the age groups 30-35 and above (again the age cutoff is country-dependent), the specificity of both tests is similar. All studies in which HC 2 or GP 5+/6+ PCR were added to cytology as the screening method, showed that, in combination, women with both normal cytology and absence of HPV DNA have an extremely low risk of developing cervical cancer in the (predicted) 10+ subsequent years. expected from increasing screening intervals and offering better coverage of the population at risk.
What is thus ahead of us?
Screening probably remains the only reasonable option for adult women who may never receive prophylactic vaccines on time. Next generations may witness an entirely different scenario in which adolescent vaccination may be common and cervical cancer much rarer. However, having available an excellent novel technology is probably not enough. Vaccines or better screening tools will only work among women who receive vaccination or benefit from screening; thus issues of cost and coverage are essential. These are political and social issues, not technical anymore. Proper follow up of women at risk (either because of being carriers of high risk HPV or of advanced CIN) requires adequacy of the logistics and infrastructure, trained medical services and health education. These have all proven to be difficult in many settings in Mexico and Latin America and urban areas may preferentially receive the preventive efforts under consideration.
Advancing in cervical cancer prevention probably requires a multi-front battle to be fought. Social awareness of the problems created by cervical cancer and of the novel advances in the knowledge of its etiology is of prime importance. Empowering women and their male partners with updated health education seems an initial step that cannot be avoided. Incorporating in a reasonable manner novel technology would make screening less demanding in terms of number of visits and more efficient in terms of protection conferred by each visit. Supporting current efforts in vaccine development and testing will help in this educational respect and will train professionals and populations in the acceptance of the vaccination strategy. Adopting a scientific approach to these matters over and above vested medical interests is the crucial responsibility of the clinical and public health societies.
This monograph offers an excellent platform where to ground the effort. It includes seventeen chapters prepared by experts on the various aspects of the field, describing the issues the options and the results available. The achievement of such a task at the right time also indicates that the Mexican public health community is strongly supported by the international scientific community in the cervical cancer field and thus that future scientific support should be available when needed. It is our challenge to reduce the burden of cervical cancer mortality, an infectious disease with known and highly efficient methods of prevention. The future should be brighter than it has ever been in this respect for the developing parts of the world.
I sincerely hope you enjoy the effort F Xavier Bosch*
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Cáncer cervical :
A escah rn~mdiaI, cada ano ociirreii caii inedio --millóri de c~iso5 de iiiicer ct>n ical, la 11iii:ld de los cuales mueren por esta caus~i. Estai citra, se relacionan estreclimie~ite con el ni\ el socioecontmico alcLinrado, por lo que la carga de eníermedaii afecta intensameiilc a los pdíses e11 desarrollo. Actualmente eiiteniicmos las c a~i a s del c ancer ceri ical '-novedosos métodos de prevención se están desarroll,iiiiio L adnptaiido en l n práctica médica.
Esperemos que éste sea el inicio de una era cn la que ocurra Liiia drástica reducción del cáncer ter\-ical en el irnbito niiindial. hléxico presenta un cúmulo dc factores de riesgo p x a el cáncer ceri ical. La prel-aleiicia de ADN del \ irus de papiloma liunicmo IVIJH) en mujeres rnajmcs de 35 afios de edad alcanza hasta l?"', la paridad es elex ;ida en la ma)-oría de los grupos sociales v el programa de tamir'ije tiene cobertura limitada en g r m lxrte d? la p0b!acló11.
Pese a grandes csi~ierros, 1' 1 orgaiiiracióii de programas de tamizaje como loi disefiado.; e iin~~lan-tados en Norteamérica y en ,ilpnos paises de Europa 1ia1i tenido ésito limitado.
No se ha podido demostrar, en la II~J! «ría de 12. poblacio~ies, que el mejoramiento dc loi programa.; ~i c tmiizaje b;isados en citologia disniinuva ¡a mortalidad por ccíncer cer.i-ical corno coniec~ie~ici~i de 1, ) inipl~ii-tacióii de diclios programas.
Este escenario es >-ha sido frustraiiteinente siniilar al de otros paises de la Regicin. Las estini,iiioiies aci~ia-les del número de casos de c,íiicer ccr1-¡cal in\ a w i iiidican que aún ocurren alrededor de 711 000 i i~i t i \ os casos aiiuales en Centroamérica y Suram(.ric,i, coi? una alta tasa de mortalidad.
El desarrollo de 1~ tecnología para la ideiitiiicacitin del XDN del 1'Pl-l e11 células extoliadas del cérl-i\ a principios de los afios SO produjo Lin gr~iii ~u g e de este c~i n i p .
Con estos inétodos, los estiidios epideiiUnl6giciis pudieron confirmar que la mi\-orín de !J.; ,i\(~ii;iiioiit~s de riesgo ilhcr\ ada.; se ;iel?eii en gran medida a la preienci, persisiciiic iici .,iD\; del '\ i:i 1. Este hallazgo e i de impoi.taiic!a capihl debido a qlic los tipos de VPH de a1:o riesgo parecen ser iiccesnrios pi"i el desarrollo dtl todos 10s casos de cinccr ccr\-icai cii r! I I I L I I~~O . En coiiseciiencia, la estr,itegia para la pre\ención lia e\ olucioii,ido ripidamente l i a c~~~ la iiicorpor,icicín de p r~~c b a s de LT' H ccmo lierraniienta de tarnizaje J . hacia la ?\ aiu,ición de riiier-as ;.acunas contra el \' I'H.
Aiortu~i~id~i~nente, el iiúriiero de tipos de 1'PH in-1 cilucrad«s en el cáncer cervical i n~ asor es liniiiado. T¿ii,i \ cicu~i~i q~~e¡iiiclu~-era ,i los siek t i p s 1112s comuiie.s de VPH en c! c;incor ter\-icai (VlW ! 6, !G,l5,11,??, 52 x7 58) e\ it,irí,i 8 7 , ) de los casos en las ni.~ijeres sac~;iiadas. iiein;l.s, cl riesgo de cincer cer7-ical p r a c:iaiqiiier tipo de los 15 1'PI-1 ide alto riesgo iio es eshdísticamente diicreiitc del riqgo reportado p r ; i los tipos más coniunes, quuon (4 Vl'l 1 16 el 1' 1' 1 I 1s. lle ;icuercic, con la e l iiieiici~ rccitmic, 1,is priiebas ~eiieric~as de VPI 1 de d i o ricigo han dc 5c.r saiicicnics para el tarnizaje y manejo de paiii.liici. Lai \ ~icunas de YPl-I toiI;i\ ia esián siciido e~-aIu,iii;ii, puo ' 1 cquiyo para redizar prueljas de 1' 1' 1 1 \-' 1 ec!d diipniblc coinrrcialmente con licencia de l . : F l l i (Fooii and D r i i~ ,Zdn~inist:.atioii) de Esixios L'iiidos Jt. Anl.érici,.
i;t. ha pi11~iic~do iin n::i~nero s~ificieiite de i,it~idins bien rt~alirados t71i 10% qui' se li,in ~~tilizado est,i p r~i i h i gcrieric~, 'isi icilno algunos de los mejores métodos dc Rt~iii611 c11 C,iiicii~ dc Po1inicra';a iPCR.
poi-iILis iiglx ci? i!ifilCii c!isp~~nibIc.;. I1icl-w i ' i t~~c i i~i Iim Jcmostr,;cio ~o i i~i~~c i i t (~i~i i~~i i i~ qlw imic l~ prucba ~l i~c~i p t i i r~i iic híbrido> Z ( ( !!-2: conio 1,; GP55t6tPCR:
EiA tielitw iei~~ibi!iciades p,ira r:copix,G,~ iiitracpitelid it,ri i c~l ? (\I('-?)
1. c'iiiccr c c n i c~l iguales o significati\.,irneiite incjc\rt.s que 1 .
1 de ia citologia ct,r\ ical. Viiigúii estudio e11 coii~iicioncs ioiiiral~das lia de~noi;tr,ido q~i c l~ ci!i>logia ie;i s~ipcrior a las pr~icba. de \'!'H En cm~bio, 1' 1 e.;peiihiidad de 125 pr~1eb;ts de \.PH es dependiente de 1' 1 eil~ii. En los grupos de edad . , joi.efieda e s p e n ; c ; p ;~-, j
L,L,L,c,ai
A-uc lar a pr::ebas de VPH es : : : As baja que la de la cit~logí~i; en cambio, en los grupos de edad de 70-35 años y más 1 IJ edad de corte depende del país) la especificidad de ambas pruebas es similar. Todos los estudios donde se agregó Cf l-2 o (X+ /6+ PCR U la citología como método de tamiz'ije demoskaron qiie las m~ijeres con una citología norinal ! r ausencia del :4DL del VPtl tienen u11 riesgo sumamente bajo de iiesarrollar cincer ten-ical en los 10 o más años siguientes ipreiiicciones). El aumento de los intervalos de tamizaje la mayor cobertura de la población en riesgo producirían ganancias importante5 en la efectividad >-reducción de costos.
¡Qué depara el futurot
El tamizaje probablemente sigue siendo la única opción razonable para las niujeres adultas con pocas posibilidades de recibir \.acunas profilácticas a tiempo. Las generaciones futuras podrían v i~i r un escenario totalmente diferente donde la vacunación de adolescentes sería común y el cáncer cervical muclio menos frecuente.
La disponibilidad de nueva y excelente tecnología quizá no sea suficiente. Las vacunas y los métodos mejorados de tamizaje sólo fiincionarán para las m~ijeres que los reciban. En este aspecto, los temas de costos Jcobertura se vuel\-en esenciales, y el aspecto técnico q~ieda solventado para tratar de resol\-er los grandes enigmas políticos sociales que se generen. El seg~ii-miento apropiado de 1' 1s mujeres en riesgo (ya sean portadoras de VPH de alto riesgo o de NIC avanzada) requiere de adecuación logística e infraestriict~ira, así como de ser] icios médicos c,ipacitados I; educación para la salud. Todos estos Iiaii sido temas difíciles en muchos dmbitos en México y América Latina. Además, las Arcas ~irbaiias suelen concentrar los esfuerzos pre~mtivos mencionados.
El avance ci: la yre: ciic!:in ~ic.1 r i ! ? c i r ter. ica! prubal~leinente reqiiierc de ~1i1,i l~aialla dc niiiltiplei t r~~i t t '~; . LJ c o n c i~n~i a soci~l dc 10s j'rol~ltvmi C J L I W~O S por el cir:ccr ccr\ ical y dc 1o.s niie\-oi a 1 ai1ct.h t'n t . 1 coiiocimieiito de SLI etiologí,~ e i primordial. El empocieramiento de 1,ii mujeres \ i~i s paici'is masc~iliniis coi1 ed~~cación actualizada iollrt. la ialii~l pnrrce ser el primer p x x~ impre-cindiblc. Ln incorpor,icicin iie 1,~ iiiie\-A ttcriologí,i dc inancr~i raroncil~le liaría el tamiraie menos demaiidantt. tu1 c~i~n t o a número de 1-isitai x~ más eficiente en cii~nlo a la proteccih ~t q g a d a en cada \-isit'i. El resy,iI~io a lo.¡ estiierros actuales de ileiarrollo y t.\-aluación de ~-;iciir~;is será de grdn iitiIidc1d cii la ediicación ! iapacitacicín de los profcsionales y poblaciones para la act,ptación de la cstraiegia de vaciiiiadó~i. LA adopciSn clei ciiiiiq~i~ ii~iiiiiico a estos problemas rn,ís allá d e intereses inédicos \-elados es rcspo~isabilid~id de las socied~des médicas >-de salud pública.
Esta monograiía provee una excelente platafornia para ciinentar estos est~ierzos. Está contorinad'~ por 17 capítulos preparados por expertos t.n los diferentes q e c t o s de esta irea del conocimiento, en los que sc describen los avances ! . rcs~~ltadns disponibles e11 la actualidad. Para coad~-uvar a resol~w el proble~nd dei cincer cen-ical la cornuni~1ad mexicana de sal~id pública está iirmernente respali1,ida por la coinuiiidad cieniíiica internacional, en esta área del conocimiento. Nuci;tro reto es reducir la carga de la mortalidad pos cCíncer ten-ical, el c i d actuLi1inente se considera como una enfermedad iniecciosa que puede coriil~atirsc coi1 inéiodos prc\ entivos conocidos !-altamente eficientes. En este aspecto, se espera un I~ituro ~n á s brillante que nunca para las regiones del mundo en desarrollo.
E~W O sii~ceran~ente que disfruten de este esfuerzo.
